Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS

Completed · Phase 3

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.

Key facts

Study ID
NCT00021697
Run by
Avanir Pharmaceuticals
People needed
100
Starts
2001-01-01
Expected to finish
2002-04-01
Last updated by the study team
2016-07-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.